Get to know our clinical trials
Trial of rapcabtagene autoleucel versus rituximab in participants with severe refractory diffuse diffuse cutaneous systemic sclerosis
THE PURPOSE OF THIS STUDY IS TO FIND OUT IF YTB323 IS SAFE AND EFFECTIVE (IF IT CAN HELP) IN PEOPLE WITH SEVERE REFRACTORY ESCD.
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE II, MULTICENTER, RANDOMIZED, OPEN-LABEL, EVALUATOR-BLINDED, ACTIVE-CONTROLLED, MULTI-PART, 3-YR, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH RAPCABTAGENE AUTOLEUCEL VS. RITUXIMAB IN PARTICIPANTS WITH SEVERE REFRACTORY DIFFUSE DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.
- Code EudraCT: 2023-510380-34
- Protocol number: CYTB323K12201
- Promoter: Novartis
- Molecule/Drug: YTB323
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.